Established patent firm with exceptional pharmaceutical sector knowledge
Our client portfolio covers the spectrum of small businesses to industry leading FTSE 100 companies, including start-ups, academic research organisations, university spin-outs and venture capital funds. We have built our first-class reputation on the results we achieve for our clients and much of our new business comes through recommendations.
We have once again been ranked as one of Europe’s Leading Patent Law Firms by the Financial Times and Statista, being rated Gold in the Chemistry & Pharmaceuticals category.
UK EU Referendum
On 1 January 2021 the United Kingdom (UK) left the European Union (EU). The European Patent Convention (EPC) is entirely independent from the EU. Therefore, the UK leaving the EU did not impact the UK’s membership of the EPC. As a UK-based firm of patent attorneys, Sagittarius IP continues to be able to file European patent applications and continues to be able to handle clients’ present and future cases at the EPO. A granted European patent continues to become a bundle of national patents in all validated states including the UK.